Toregem BioPharma
For a society where people are not afraid of losing their teeth
- Headquarters
- Kyoto
- Founded
- 2020
- Business Model
- B2B
- Website
- toregem.co.jp
- Total Funding
- $22.4M
- Last Round
- $2.6M Series AJun 2026
- Rounds
- 4
About
Toregem BioPharma develops regenerative treatments for tooth defects, enabling patients to regrow their own natural teeth. Founded from decades of Kyoto University research, the lead drug TRG035 blocks the USAG-1 protein that suppresses tooth growth. It targets congenital tooth agenesis and edentulous patients, advancing into Phase 2 clinical trials.
Summary
Toregem BioPharma is a Biotech company based in Kyoto, Japan, founded in 2020. It has raised $22.4M in total across 4 rounds, most recently a $2.6M Series A round in Jun 2026. Investors include Astellas Venture Management, Mitsubishi UFJ Capital and JIC Venture Growth Investments.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Jun 2026
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Create Free AccountInvestors
Similar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...